AB Science Secures Loan Repayment Deferrals to Fund R&D Operations Through 2028

Key Takeaways

• AB Science negotiated loan repayment deferrals with all financial creditors, providing immediate cash flow relief
• Two-year deferral on State-Guaranteed Loans and 12-month extension on EIB Covid credit secured
• Financial savings will be reinvested into research and development programs

---

AB Science announced April 27, 2026, that it has reached a comprehensive agreement with all financial creditors to restructure loan repayment terms, providing the French biotechnology company with enhanced financial flexibility to advance its research pipeline.

Financial Restructuring Details

The agreement encompasses two key components: a two-year deferral of State-Guaranteed Loan repayments and a 12-month extension on the European Investment Bank (EIB) Covid credit facility. This restructuring provides AB Science with significant near-term cash flow relief during a critical period for the company’s development programs.

Strategic Impact on R&D Investment

AB Science confirmed that financial savings generated from the deferred repayments will be directly reinvested into research and development activities. This strategic allocation supports the company’s ongoing clinical trials and drug development initiatives, particularly focusing on its lead compound masitinib across multiple therapeutic areas.

Market Context and Implications

The loan restructuring reflects broader challenges facing biotechnology companies in securing adequate funding for extended development timelines. For AB Science, this agreement provides operational stability while maintaining relationships with key financial partners including government-backed lenders and the EIB.

The timing of this agreement is particularly significant as AB Science continues advancing multiple clinical programs. The extended repayment timeline allows the company to allocate resources toward value-creating activities rather than debt service during crucial development phases.

Financial Outlook

This restructuring positions AB Science to maintain its research momentum without immediate refinancing pressure. The company’s ability to negotiate favorable terms with all creditors demonstrates stakeholder confidence in its long-term prospects and development pipeline potential.

The agreement provides AB Science with enhanced financial runway to execute on key clinical milestones and regulatory submissions planned through 2028.

---

Frequently Asked Questions

What does this loan restructuring mean for AB Science’s operations?

The restructuring provides immediate cash flow relief and allows AB Science to redirect funds from loan payments into R&D activities, supporting continued clinical development programs.

How long do the loan deferrals last?

State-Guaranteed Loans receive a two-year repayment deferral, while the EIB Covid credit gets a 12-month extension, providing staggered financial relief through 2028.

Will this affect AB Science’s drug development timeline?

The restructuring should positively impact development timelines by freeing up capital for R&D investment rather than debt service, potentially accelerating clinical programs.